Adocia Sa · EURONEXT:ADOC
Adocia Sa — Q3 2026 Earnings Presentation
19 slides from Adocia Sa's earnings presentation, Nov 2, 2026
Slide 1: Q3 2026 financial results and business update
Q3 2026 financial results and business update Webcast November 2, 2026
Slide 2: Forward-looking statements
Forward-looking statements ADOC This corporate presentation (the “Presentation”) has been prepared by ADOCIA S.A. (the “Company” and, together with its subsidiary, the “Group”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall m
Slide 3: Q3 Financial Results – Key points
Q3 Financial Results – Key points €8.4M €7M Lower costs Cash position as of Financing closed in October 2026 Cost-reduction measures across the September 30, 2026 €3M capital increase whole organization €4M increase in the shareholder loan agreement signed with Vester Finance Debt-free Cash runway e
Slide 4: Metabolic diseases: a large, fast-growing market primed for innovation
Metabolic diseases: a large, fast-growing market primed for innovation 2025 Global prevalence in adults1-4 By 2050… 2050 prediction 1.95B 1 in 3 adults Obesity 1B will be obese 853M 1 in 8 adults Diabetes 589M will have diabetes $20B $150B insulin market in 20245 GLP-1 receptor agonist market in 203
Slide 5: Diabetes and obesity: significant unmet needs to achieve real health impact
Diabetes and obesity: significant unmet needs to achieve real health impact Current therapies reach too few patients, for a too short time 1% People with Obesity globally treated ~50% of patients discontinue GLP-1 with branded Anti-Obesity Medication3 within the first year in real-world practice1,2
Slide 6: Adocia technologies enabling meaningful Health Impact
Adocia technologies enabling meaningful Health Impact Increase manufacturing capacity BioChaperone® AdoXLong Improve Reduce Expert in patient COGS Peptide experience delivery AdOral® AdoShell® Enable differentiated drug delivery Close the gap between healthspan and lifespan 6 6
Slide 7: BioChaperone Lispro: potential to become the best mealtime insulin
BC 222 BioChaperone® Lispro: potential to become the best mealtime insulin Blood glucose (SMBG), mmol/L, week 26, * p<0.05 ● Humalog® ● BC Lispro 11 T1D 10 * * Phase 3 of 550 people 9 * with T1D randomized with 8 3:2 ratio, 490 completers1 7 Improved glycemic FBG 1h 2h Pre 1h 2h Pre 1h 2h Bed Fastin
Slide 8: BC Lispro: strategic partnership with Tonghua Dongbao in China
BC 222 BC Lispro: strategic partnership with Tonghua Dongbao in China Partnered with 78% $2.3B of THDB revenue from THDB market cap3 insulin2 Achieved Next steps Double-digit $10M $5M $10M $20M Royalties Upfront, license 1st patient in Phase 3 Last Positive Phase 3 in Marketing Approval in China Sal
Slide 9: BC Lispro commercial distribution: $7B Global prandial insulin market in 2025
BC 222 BC Lispro commercial distribution: $7B Global prandial insulin market in 2025 China and other Asian Countries eligible for a EU/US : Regulated markets countries covered by THDB simplified registration requiring a new Phase III Main countries Main countries ال إله إال هللا محمد رسول هللا EU
Slide 10: BioChaperone offers a unique stabilization effect
BC449 BioChaperone® offers a unique stabilization effect Technical challenge API(s) Obtained with BioChaperone® Glargine (basal insuline) + Lispro (rapid insulin) Fixed Dose Combination Incompatible Pramlintide (amylin) + Human Insulin combination Glucagon + Exenatide (GLP1) Human Glucagon Ready-to-
Slide 11: Expanding the range of potential collaborations with BioChaperone
BC449 Expanding the range of potential collaborations with BioChaperone® Paid R&D collaboration Licensing agreement Partners test BioChaperone® freely and confidentially Triggered if the partner wishes to conduct an in vivo evaluation Scope: in vitro proof-of-concept Confidentiality, strategic for p
Slide 12: BC449 has been successfully developed as a pharmaceutical excipient
BC449 BC449 has been successfully developed as a pharmaceutical excipient Easy to manufacture and easily scalable • Patented amphiphilic polymer up to 2038 • Fully soluble and stable (>2 years at 2-8°C) • Available at a GMP-grade on 20-kg scale with scale-up plan reaching 3T by 2030 A safe excipient
Slide 13: AdoXLong platform: extending half-life of peptides for once-monthly injection
AdoXLong AdoXLong platform: extending half-life of peptides for once-monthly injection Biocompatible polymer covalently linked to the peptide ADOXLONG ➔ Increased half-life PLATFORM ➔ Standard manufacturing process ➔ Patent filed in Nov. 2025, all peptides could be protected till 2046 • Clear aqueou
Slide 14: AdoXLong platform: potential for once-a-month exposure in humans
AdoXLong AdoXLong platform: potential for once-a-month exposure in humans PK profile after single SC administration to rats PK profile after administration in farm pigs AdoXL Sema, SC, 60 nmol/kg Semaglutide simulation, SC, 60 nmol/kg PK data in pigs will be presented T1/2 = 32h at Obesity Week 2026
Slide 15: AdoShell: permselective hydrogel for cell therapy without immunosuppression
AdoShell® AdoShell®: permselective hydrogel for cell therapy without immunosuppression Pancreatic islets OR Stem cells Immuno-isolation from donors derived islets Ab, T cells Large entities >10nm AdoShell® Minimally surgery (laparoscopy) Free diffusion Biomaterial (hydrogel + reinforcing frame) Oxyg
Slide 16: AdoShell: ready for the clinic
AdoShell® AdoShell®: ready for the clinic TODAY T1D Cure Immuno protection Human islets Regulatory studies ongoing Function and efficacy FIH Stem cells derived islets Looking for partners Surgical procedure Other cell therapies applications Stem cells PoC with hepatic SC: Looking for partners FIH in
Slide 17: Key takeaways: one product ready for market, one technology ready for late development and 2 technologies for clinics
Key takeaways: one product ready for market, one technology ready for late development and 2 technologies for clinics Phase 3 & licensing Ambition to Ambition to Market-ready ready go to clinic go to clinic BioChaperone® Lispro BioChaperone® AdoXLong AdoShell® Partnership with Tonghua BC 449 AdoXL S
Slide 18: Q&A
Q&A 18 18
Slide 19: Thank you
Thank you 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com